[Haemodynamic investigations with the new antihypertensive drug guanfacine (author's transl)].
Guanfacine, a new centrally acting alpha-mimetic antihypertensive drug, was given to two groups of 7 patients each, one with essential and the other with renal hypertension. Both in the acute trial (after short-term intermittent initial blood pressure increase) and in the long-term treatment (4 weeks) lowering of blood pressure occurred, mediated via decrease of peripheral vascular resistance. In addition, support of cardiac function, especially of the afterload and possibly also the preload, was induced. This was demonstrated by results obtained after ergometric loading.
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002302:Cardiac Output; D004341:Drug Evaluation; D005260:Female; D016316:Guanfacine; D006146:Guanidines / Q000494:pharmacology / Q000627:therapeutic use*; D006339:Heart Rate; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D006977:Hypertension, Renal / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010648:Phenylacetates / Q000494:pharmacology / Q000627:therapeutic use*; D005082:Physical Exertion; D013997:Time Factors; D014655:Vascular Resistance / Q000187:drug effects
D000959:Antihypertensive Agents; D006146:Guanidines; D010648:Phenylacetates; D016316:Guanfacine
Hämodynamische Untersuchungen mit dem neuen Antihypertensivum Guanfacin. Kreislaufverhalten bei Hypertonikern im Akut- und Langzeitversuch, in Ruhe und unter Belastung.